Authors' recommendations: Technologically, preimplantation diagnosis can be introduced in Denmark, but not without increasing costs for the health care sector. However, these extra costs are moderate, especially when compared with the costs of many new pharmaceuticals. The PGD technique is very much demanded by potential users (families with a risk of having a diseased child), but presumably the method will be employed by a limited group of people only with a risk of having a child with relatively severe disease. From a gradualistic point of view the method is ethically preferable. A minor uncertainty concerning the possible long-term risk associated with PGD does not justify a reservation. Introduction of PGD in the public health care sector can be implemented with relatively moderate extra costs, which has to be balanced against the advantages of the method. Among these are the avoided legal abortions that are expected to have a value also.

Project Status: Completed

Year Published: 2002

URL for published report: http://www.sst.dk/publ/Publ2002/Praeimplant/Praeimplant.pdf

URL for additional information: http://www.sst.dk/English/DACEHTA/Publications_alphabetical_order/Prenatal%20diagnosis.aspx

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Denmark

Organisation Name: Danish Centre for Evaluation and Health Technology Assessment

Contact Address: National Board of Health, PO Box 1881, Islands Brygge 67, DK-2300 Copenhagen S, Denmark. Tel: 45 72 22 74 48; Fax: 45 72 22 74 07/67

Contact Name: dacehta@sst.dk

Contact Email: dacehta@sst.dk

Copyright: Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)